External Beam Radiotherapy in limited setting: Optimizing Cobalt-60 for forward planning field-in-field intensity modulation technique in nasopharyngeal cancer Irradiation
Sari
Cobalt-60 adalah salah satu modalitas teleterapi yang paling tua, namun masih digunakan di beberapa negara berkembang. Modifikasi bisa dilakukan untuk mengoptimalkan kemampuan pesawat Cobalt-60 dalam pengobatan kanker nasofaring.
Penulis mengembangkan teknik field-in-field pada pesawat Cobalt-60. Beberapa penyulit / keterbatasan berusaha disesuaikan dengan cara mengubah pemberian dosis, peletakan isosenter, collimator, dan blok. Teknik penyinaran ini menggunakan 12-15 lapangan dalam menggunakan 7-9 blok, yang diletakkan dalam 3-5 trays.
Teknik ini mampu mencapai kriteria yang ditetapkan untuk planning approval. Sembilan pasien yang telah menjalani terapi mengalami efek samping akut yang dapat diterima, dengan tingkat complete response 71%.
Teknik Forward planning field-in-field bisa digunakan untuk membantu mengatasi beberapa keterbatasan pesawat Cobalt-60 dan menunjukkan hasil yang baik.
Kata Kunci
Teks Lengkap:
PDF (English)Referensi
Fox, C., Romeijn, H. E., Lynch, B., Men, C., Aleman, D. M., & Dempsey, J. F. (2008). Comparative analysis of60Co intensity-modulated radiation therapy. Physics in Medicine and Biology, 53(12), 3175-3188. https://doi.org/10.1088/0031-9155/53/12/007
Page, B. R., Hudson, A. D., Brown, D. W., Shulman, A. C., Abdel-Wahab, M., Fisher, B. J., & Patel, S. (2014). Cobalt, linac, or other: What is the best solution for radiation therapy in developing countries? International Journal of Radiation Oncology*Biology*Physics, 89(3), 476-480. https://doi.org/10.1016/j.ijrobp.2013.12.022
Lee, N., Harris, J., Garden, A. S., Straube, W., Glisson, B., Xia, P., Bosch, W., Morrison, W. H., Quivey, J., Thorstad, W., Jones, C., & Ang, K. K. (2009). Intensity-modulated radiation therapy with or without chemotherapy for Nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225. Journal of Clinical Oncology, 27(22), 3684-3690. https://doi.org/10.1200/jco.2008.19.9109.
Lee, A. W., Ng, W. T., Pan, J. J., Poh, S. S., Ahn, Y. C., AlHussain, H., Corry, J., Grau, C., Grégoire, V., Harrington, K. J., Hu, C. S., Kwong, D. L., Langendijk, J. A., Le, Q. T., Lee, N. Y., Lin, J. C., Lu, T. X., Mendenhall, W. M., O'Sullivan, B., … Wee, J. T. (2018). International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 126(1), 25-36. https://doi.org/10.1016/j.radonc.2017.10.03
Podgoršak, E. B. (2005). Radiation oncology physics: A handbook for teachers and students. IAEA. https://www-pub.iaea.org/mtcd/publications/pdf/pub1196_web.pdf
Sharma, S. (2014). Challenges of small photon field dosimetry are still challenging. Journal of Medical Physics, 39(3), 131. https://doi.org/10.4103/0971-6203.138998
Hu, W., Ding, W., Yang, H., Shao, M., Wang, B., Wang, J., Wu, S., Wu, S., Jin, L., & Ma, C. C. (2009). Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 93(3), 488-491. https://doi.org/10.1016/j.radonc.2009.06.030
Bossi, P., Parolini, D., Bergamini, C., Locati, L. D., Orlandi, E., & Franceschini, M. (2009, May 20). TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC) | Journal of clinical oncology. ASCO Publications. https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.6046
Kim, T. H., Ko, Y. H., Lee, M. A., Kim, B., Chung, S. R., Yoo, I. R., Jung, C., Kim, Y., Kim, M. S., Sun, D., Hong, Y. S., Lee, K. S., & Kang, J. (2008). Treatment outcome of cisplatin-based concurrent Chemoradiotherapy in the patients with locally advanced Nasopharyngeal cancer. Cancer Research and Treatment, 40(2), 62. https://doi.org/10.4143/crt.2008.40.2.62
DOI: https://doi.org/10.32532/jori.v12i1.119 <
Article metrics
Abstract views : 377 | views : 276Refbacks
- Saat ini tidak ada refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.